{"id":2486,"date":"2024-11-14T04:14:41","date_gmt":"2024-11-14T04:14:41","guid":{"rendered":"https:\/\/medicine.nus.edu.sg\/medphc\/?p=2486"},"modified":"2024-12-16T08:16:45","modified_gmt":"2024-12-16T08:16:45","slug":"customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/","title":{"rendered":"Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone  wp-image-2562\" src=\"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2024\/11\/20240919-MLE-300x169.jpg\" alt=\"\" width=\"950\" height=\"535\" srcset=\"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2024\/11\/20240919-MLE-300x169.jpg 300w, https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2024\/11\/20240919-MLE-1024x576.jpg 1024w, https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2024\/11\/20240919-MLE-768x432.jpg 768w, https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2024\/11\/20240919-MLE.jpg 1280w\" sizes=\"auto, (max-width: 950px) 100vw, 950px\" \/><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>Summary<\/strong><\/span><br \/>\n<span style=\"font-size: 14pt;\">Background Tyrosine kinase inhibitors (TKIs) are currently the standard therapy for patients with non-small cell lung cancer (NSCLC) bearing mutations in epidermal growth factor receptor (EGFR). Unfortunately, drug-acquired resistance is inevitable due to the emergence of new mutations in EGFR. Moreover, the TKI treatment is associated with severe toxicities due to the unspecific inhibition of wild-type (WT) EGFR. Thus, treatment that is customised to an individual\u2019s genetic alterations in EGFR may offer greater therapeutic benefits for patients with NSCLC.<\/span><\/p>\n<p>( Full Article : <a href=\"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105356\">https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(24)00392-X\/fulltext )<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Summary Background Tyrosine kinase inhibitors (TKIs) are currently the standard therapy for patients with non-small cell lung cancer (NSCLC) bearing mutations in epidermal growth factor receptor (EGFR). Unfortunately, drug-acquired resistance is inevitable due to the emergence of new mutations in EGFR. Moreover, the TKI treatment is associated with severe toxicities due to the unspecific inhibition [&hellip;]<\/p>\n","protected":false},"author":9340,"featured_media":2562,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[5],"tags":[],"class_list":["post-2486","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publications"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer - Pharmacology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer - Pharmacology\" \/>\n<meta property=\"og:description\" content=\"Summary Background Tyrosine kinase inhibitors (TKIs) are currently the standard therapy for patients with non-small cell lung cancer (NSCLC) bearing mutations in epidermal growth factor receptor (EGFR). Unfortunately, drug-acquired resistance is inevitable due to the emergence of new mutations in EGFR. Moreover, the TKI treatment is associated with severe toxicities due to the unspecific inhibition [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharmacology\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-14T04:14:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-16T08:16:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2024\/11\/20240919-MLE.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"cheongyokeping\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"cheongyokeping\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\\\/\"},\"author\":{\"name\":\"cheongyokeping\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#\\\/schema\\\/person\\\/b583108ae48c87bbb39bf073d9065c35\"},\"headline\":\"Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer\",\"datePublished\":\"2024-11-14T04:14:41+00:00\",\"dateModified\":\"2024-12-16T08:16:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\\\/\"},\"wordCount\":112,\"publisher\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/wp-content\\\/uploads\\\/sites\\\/33\\\/2024\\\/11\\\/20240919-MLE.jpg\",\"articleSection\":[\"Publications\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\\\/\",\"url\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\\\/\",\"name\":\"Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer - Pharmacology\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/wp-content\\\/uploads\\\/sites\\\/33\\\/2024\\\/11\\\/20240919-MLE.jpg\",\"datePublished\":\"2024-11-14T04:14:41+00:00\",\"dateModified\":\"2024-12-16T08:16:45+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/wp-content\\\/uploads\\\/sites\\\/33\\\/2024\\\/11\\\/20240919-MLE.jpg\",\"contentUrl\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/wp-content\\\/uploads\\\/sites\\\/33\\\/2024\\\/11\\\/20240919-MLE.jpg\",\"width\":1280,\"height\":720},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#website\",\"url\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/\",\"name\":\"Pharmacology\",\"description\":\"Just another WordPress site\",\"publisher\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#organization\",\"name\":\"Pharmacology\",\"url\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/wp-content\\\/uploads\\\/sites\\\/33\\\/2022\\\/06\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/wp-content\\\/uploads\\\/sites\\\/33\\\/2022\\\/06\\\/logo.png\",\"width\":467,\"height\":69,\"caption\":\"Pharmacology\"},\"image\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#\\\/schema\\\/person\\\/b583108ae48c87bbb39bf073d9065c35\",\"name\":\"cheongyokeping\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b385c80b89c1b79677148017b456df8d29ece7f2b68d54d920ff15561673b7a2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b385c80b89c1b79677148017b456df8d29ece7f2b68d54d920ff15561673b7a2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b385c80b89c1b79677148017b456df8d29ece7f2b68d54d920ff15561673b7a2?s=96&d=mm&r=g\",\"caption\":\"cheongyokeping\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer - Pharmacology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer - Pharmacology","og_description":"Summary Background Tyrosine kinase inhibitors (TKIs) are currently the standard therapy for patients with non-small cell lung cancer (NSCLC) bearing mutations in epidermal growth factor receptor (EGFR). Unfortunately, drug-acquired resistance is inevitable due to the emergence of new mutations in EGFR. Moreover, the TKI treatment is associated with severe toxicities due to the unspecific inhibition [&hellip;]","og_url":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/","og_site_name":"Pharmacology","article_published_time":"2024-11-14T04:14:41+00:00","article_modified_time":"2024-12-16T08:16:45+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2024\/11\/20240919-MLE.jpg","type":"image\/jpeg"}],"author":"cheongyokeping","twitter_card":"summary_large_image","twitter_misc":{"Written by":"cheongyokeping","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/#article","isPartOf":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/"},"author":{"name":"cheongyokeping","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#\/schema\/person\/b583108ae48c87bbb39bf073d9065c35"},"headline":"Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer","datePublished":"2024-11-14T04:14:41+00:00","dateModified":"2024-12-16T08:16:45+00:00","mainEntityOfPage":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/"},"wordCount":112,"publisher":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#organization"},"image":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2024\/11\/20240919-MLE.jpg","articleSection":["Publications"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/","url":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/","name":"Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer - Pharmacology","isPartOf":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/#primaryimage"},"image":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2024\/11\/20240919-MLE.jpg","datePublished":"2024-11-14T04:14:41+00:00","dateModified":"2024-12-16T08:16:45+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/customised-design-of-antisense-oligonucleotides-targeting-egfr-driver-mutants-for-personalised-treatment-of-non-small-cell-lung-cancer\/#primaryimage","url":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2024\/11\/20240919-MLE.jpg","contentUrl":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2024\/11\/20240919-MLE.jpg","width":1280,"height":720},{"@type":"WebSite","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#website","url":"https:\/\/medicine.nus.edu.sg\/medphc\/","name":"Pharmacology","description":"Just another WordPress site","publisher":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medicine.nus.edu.sg\/medphc\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#organization","name":"Pharmacology","url":"https:\/\/medicine.nus.edu.sg\/medphc\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#\/schema\/logo\/image\/","url":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2022\/06\/logo.png","contentUrl":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2022\/06\/logo.png","width":467,"height":69,"caption":"Pharmacology"},"image":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#\/schema\/person\/b583108ae48c87bbb39bf073d9065c35","name":"cheongyokeping","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b385c80b89c1b79677148017b456df8d29ece7f2b68d54d920ff15561673b7a2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b385c80b89c1b79677148017b456df8d29ece7f2b68d54d920ff15561673b7a2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b385c80b89c1b79677148017b456df8d29ece7f2b68d54d920ff15561673b7a2?s=96&d=mm&r=g","caption":"cheongyokeping"}}]}},"_links":{"self":[{"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/posts\/2486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/users\/9340"}],"replies":[{"embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/comments?post=2486"}],"version-history":[{"count":4,"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/posts\/2486\/revisions"}],"predecessor-version":[{"id":2564,"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/posts\/2486\/revisions\/2564"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/media\/2562"}],"wp:attachment":[{"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/media?parent=2486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/categories?post=2486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/tags?post=2486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}